NYSE: CAH · Medical Distribution
Cardinal Health (CAH) fair value and price range
As of 14 Nov 2026, Faircurve's model values Cardinal Health (CAH) at $288.57 a share. The stock last closed at $283.85, which puts the model's fair value 1.7% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. Cardinal Health, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $278.68 to $288.57 (+3.5%). The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move.
What the model makes of itThe price of $283.85 is 1.7% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 4 Feb 2027. Options prices imply a move of about 8% either way over the next month. On the model's Quality Momentum list since 9 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give CAH?
The calibrated range for CAH over 63 trading days is $259.30 to $312.14. It sits around the last close, and its width comes from the volatility that CAH's own options imply (27% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $174.60 to $459.87. In 52% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Cardinal Health, Inc. (CAH) operates as a global, integrated provider of healthcare services and products. Its reach spans the United States, Canada, Europe, Asia and other international markets. It sits in Healthcare, under Medical Distribution.
Faircurve's model puts the fair value of Cardinal Health at $288.57 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $278.68, so the fair value moved +3.5%. The model says the stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move. The calibrated range over 63 trading days is $255.46 to $310.81. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, so no verdict is shown. The grade looks at input completeness, comparable agreement and outcome spread. It does not say whether the fair value is right.
Cardinal Health scores 84 out of 100 overall on the model's quality measure, against comparable companies. Profitability and earnings quality each score 100. ROIC is 314.4% against a peer median of 29.8%, and FCF / net income is 2.70x against a peer median of 1.14x. The model compares the company with Henry Schein, Inc., Boston Scientific Corporation, Edwards Lifesciences Corporation, Becton, Dickinson and Company, IDEXX Laboratories, Inc. and Humana Inc.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does CAH report earnings, and how has the stock reacted?
Cardinal Health's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 3.7% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. CAH's 30 day implied volatility works out to about 7.9% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CAH's last 8 reports, ignoring direction, was 4.8%.
What the options market has priced for a month's move in CAH
How does CAH score on business quality?
Cardinal Health's overall quality score is 84 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 100 | 314.4%ROIC | 29.8% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | 2.70xFCF / net income | 1.14x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 65 | 14.2%Revenue growth, trailing | 5.0% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 75 | 2.3%Net buybacks / market value | 3.7% |
| Balance sheetNet debt to EBITDA and interest coverage. | 61 | 0.99xNet debt / EBITDA | 1.04x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 75 | 0.4 ptsEBITDA margin downside volatility, 5y | 0.2 pts |
How does CAH compare with similar companies?
The companies in medical distribution closest to Cardinal Health in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| COR Cencora, Inc. | $356.94 | $377.17 | +5.7% | Low evidence grade |
| MCK McKesson Corporation | $1,105.04 | $1,118.05 | +1.2% | Low evidence grade |
| HSIC Henry Schein, Inc. | $84.96 | $89.58 | +5.4% | Fairly valued |
| BSX Boston Scientific Corporation | $43.69 | $52.05 | +19.1% | Undervalued |
| EW Edwards Lifesciences Corporation | $107.11 | $88.12 | -17.7% | Overvalued |
| BDX Becton, Dickinson and Company | $216.47 | $215.74 | -0.3% | Fairly valued |
| IDXX IDEXX Laboratories, Inc. | $700.65 | $568.18 | -18.9% | Overvalued |
| HUM Humana Inc. | $461.25 | $411.63 | -10.8% | Fairly valued |
What the comparable companies' multiples alone would give for CAH, the peer-implied price, is $322.00 a share on this run. The fair value weighs that against the company's own multiple.
Cardinal Health at a glance
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets.
- Market value
- $65.0B
- Sector
- Healthcare
- Industry
- Medical Distribution
- Revenue expected, next twelve months
- $272.2B
- Consensus revenue growth, next fiscal year
- +4.7%
- Analysts with estimates
- 8
- Beta to the US market
- -0.10
- First valued by Faircurve
- 1 May 2026
How the fair value is worked out: the model prices Cardinal Health on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for CAH was $278.68. As of 14 Nov 2026 it is $288.57, a change of +3.5%. The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Cardinal Health's valuation
Is Cardinal Health stock undervalued or overvalued?
Faircurve's model puts CAH's fair value at $288.57 a share against a last close of $283.85, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is CAH's fair value?
$288.57 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $174.60 to $459.87.
What price range does the model give CAH?
$259.30 to $312.14 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Cardinal Health report earnings next?
The next report is scheduled for 4 Feb 2027. Companies can move their dates.
How much has CAH moved on past earnings reports?
Across its last 8 reports the median two session move was 4.8%, ignoring direction. The largest was +16.0% around the report of 30 Oct 2025.
How confident is the model in this valuation?
The model's evidence grade for CAH is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on CAH
The model has an idea open on CAH under Quality Momentum since 9 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CAH with their outcomes. A free account is enough.